Mitapivat and Dronedarone: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Dronedarone
Mitapivat
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased mitapivat exposure and reduced CYP3A4 substrate exposure
Interaction Deep Dive
Avoid coadministration of mitapivat (a CYP3A4 substrate) and moderate CYP3A4 inhibitors that also are sensitive CYP3A4 substrates with NTI as it may increase mitapivat exposure and/or reduces exposure of the sensitive CYP3A4 substrates1. If coadministration is required, do not titrate beyond 20 mg twice daily, and monitor Hb, for adverse reactions and for loss of therapeutic effect 2.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of mitapivat; induction of CYP3A4-mediated metabolism by mitapivat
Literature reports
2 reports — tap to read
a) In drug interaction studies, coadministration of mitapivat with midazolam (a sensitive CYP3A4 substrate) decreased midazolam AUC(inf) and Cmax by 21% and 19% with mitapivat 5 mg twice daily, by 43% and 39% with mitapivat 20 mg twice daily, and by 57% and 52% with mitapivat 50 mg twice daily, respectively 2. Similarly, midazolam AUC (inf) and Cmax decreased by 65% and 59%, respectively, with mitapivat 100 mg twice daily 1.
b) Coadministration of mitapivat with fluconazole, a moderate CYP3A4 inhibitor, increased mitapivat AUC(0 to 12) and Cmax by 2.6-fold and 1.6-fold, respectively, following administration of mitapivat 5, 20 or 50 mg twice daily 21.
Common questions
Can I take Mitapivat and Dronedarone together?
Increased mitapivat exposure and reduced CYP3A4 substrate exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Mitapivat and Dronedarone interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Mitapivat or Dronedarone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
Keep reading about Dronedarone
Keep reading about Mitapivat
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist